Post‑screen Interfaces Are The Next Big Tech Shift You Need To See Coming 
Understanding the Promise & Perils of Artificial Intelligence 
20i Launches The Web Industry’s First Unlimited Managed Hosting Assistant 
Information Security as a Core Business Responsibility 
B2BROKER Enhances B2CORE Across Web and Mobile, Advancing Its Brokerage Infrastructure Revolo Biotherapeutics to Host Virtual KOL Event on ‘1104: A First-in-Class Peptide for Eosinophilic Esophagitis (EoE) and Allergic Disease
NEW ORLEANS and CAMBRIDGE, United Kingdom, Aug. 08, 2023 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (“Revolo”…
Revolo Biotherapeutics to Host Virtual KOL Event on ‘1104: A First-in-Class Peptide for Eosinophilic Esophagitis (EoE) and Allergic Disease
NEW ORLEANS and CAMBRIDGE, United Kingdom, Aug. 08, 2023 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (“Revolo”…
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results
Resmetirom new drug application (NDA) submitted to the U.S. Food and Drug Administration NASH disease education…
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results
Resmetirom new drug application (NDA) submitted to the U.S. Food and Drug Administration NASH disease education…
LifeSci Consulting Expands with Global Operations Consulting Capability and London Office
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) — LifeSci Consulting, a boutique strategy consulting and…
LifeSci Consulting Expands with Global Operations Consulting Capability and London Office
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) — LifeSci Consulting, a boutique strategy consulting and…
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
Initial clinical results from Phase 2 SUMMIT trial in NonAdvSM along with updated data from…
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
Initial clinical results from Phase 2 SUMMIT trial in NonAdvSM along with updated data from…
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma
BASKING RIDGE, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma
BASKING RIDGE, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August
FARMINGTON HILLS, Mich., Aug. 08, 2023 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a…
Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August
FARMINGTON HILLS, Mich., Aug. 08, 2023 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a…
Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results
– Initiated dosing at U.S. sites for VIRAGE, the Phase 2b clinical trial of VCN-01…
Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results
– Initiated dosing at U.S. sites for VIRAGE, the Phase 2b clinical trial of VCN-01…
Grace Breeding’s Environmentally Friendly WDS Climate Stress Tolerance Solution Receives its First European Product Registration in Germany
– Grace Breeding’s WDS, a proprietary and environmentally friendly formula to counteract crop climate stress,…
Grace Breeding’s Environmentally Friendly WDS Climate Stress Tolerance Solution Receives its First European Product Registration in Germany
– Grace Breeding’s WDS, a proprietary and environmentally friendly formula to counteract crop climate stress,…
Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead
First dual coronavirus–norovirus oral antiviral is scheduled for Phase 1 in healthy volunteers In vitro…
Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead
First dual coronavirus–norovirus oral antiviral is scheduled for Phase 1 in healthy volunteers In vitro…
Mersana Therapeutics Announces Second Quarter 2023 Financial Results
Organization fully focused on product candidates and collaborations based on next-generation ADC platforms Capital resources…
Mersana Therapeutics Announces Second Quarter 2023 Financial Results
Organization fully focused on product candidates and collaborations based on next-generation ADC platforms Capital resources…